Additionally, eptifibatide and prostacyclin (PGI2), which target platelet glycoprotein GPIIB-IIIA binding, and platelet’s G-protein coupled receptor activation, respectively, inhibited the platelets’ effect on ovarian cancer spheroids, suggesting the involvement of these receptors also in the functional interactions of platelets and ovarian cancer spheroids. This evidence concerns the gene ITGA2B and ovarian cancer.